New Key Statistics Module, Z-Score and F-Score
NAS:ATRA Key Ratios
| Market Cap $ M | 40.61 |
| Enterprise Value $ M | 50.60 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | 1.26 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 34.00 |
| EPS (TTM) $ | -53.25 |
| Beneish M-Score | 131.84 |
| 10-y EBITDA Growth Rate % | -5.10 |
| 5-y EBITDA Growth Rate % | 17.50 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.22 |
| EV-to-EBITDA | -0.23 |
| PEG | -- |
| Shares Outstanding M | 4.90 |
| Net Margin (%) | -671.70 |
| Operating Margin % | -669.19 |
| Pre-tax Margin (%) | -671.65 |
| Quick Ratio | 0.50 |
| Current Ratio | 0.59 |
| ROA % (ttm) | -109.12 |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -164.75 |
| Dividend Yield % | -- |
| Altman Z-Score | -21.74 |
ATRA Number of Guru Trades
ATRA Volume of Guru Trades
Gurus Latest Trades with NAS:ATRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:ATRA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Atara Biotherapeutics Inc Insider Transactions
No Available Data
News about NAS:ATRA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers